Drugs / PF-06755992
last change Mar 2023 re-read 9 days ago

PF-06755992

Developed for
prostate neoplasm
Investigated by
Pfizer

Trials 1

201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02616185 Dec 2015 → Feb 2021 prostate neoplasm Pfizer Terminated No outcome recorded Stop: Business

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as PF-06755992 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02616185 ↗
Route Intramuscular “patients with mCRPC received intramuscular PrCa VBIR” PMID 36948505 ↗ Mar 2023